Home
This site is intended for healthcare professionals
Share

Description

This activity is supported by an independent education grant from BMS. This online education program has been designed for healthcare professionals globally, excluding the UK.

Join experts Fernando Martinez, MD, and Corey Kershaw, MD, for a case-based exploration of early risk identification in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). This session examines how subtle respiratory symptoms are frequently overlooked, demonstrating how structured risk profiling can prevent diagnostic delays before overt, irreversible lung function loss occurs.

This is Module One of Four. Modules Two, Three, and Four can be found here.

Session Highlights

  • Recognize that non-specific symptoms like dry cough and subtle dyspnea represent high-risk flags in RA patients that require prompt investigation.
  • Apply the 2023 ACR/CHEST guidelines to conditionally screen at-risk, asymptomatic patients using structured risk assessment tools.
  • Evaluate patient risk inputs—including high anti-CCP serology, smoking history, and RA duration—to trigger timely PFT and HRCT referrals.
  • Implement cross-specialty collaboration pathways between rheumatology and pulmonology to establish joint checkpoints for early detection.

Target Audience

This activity is intended for pulmonologists, rheumatologists, thoracic radiologists, pathologists, pulmonology nurse practitioners, and physician assistants/associates who are central to the diagnosis and management of IPF and PPF. It is also designed for general practitioners, respiratory therapists, pharmacists, and other multidisciplinary healthcare professionals involved in the care of patients with pulmonary fibrosis.

Faculty

Dr Fernando Martinez is a Professor in the Division of Pulmonary Medicine and Interim Chair of the Department of Medicine at the University of Massachusetts Chan Medical School in Worcester, Massachusetts. Holding an MD and MS, he is a leading clinician and researcher with a long-standing commitment to academic medicine, patient care, and multidisciplinary strategies in respiratory medicine.

Dr Corey Kershaw is a Professor in the Department of Internal Medicine within the Division of Pulmonary and Critical Care Medicine at UT Southwestern. He serves as the Clinical Services Chief for the Division of Pulmonary and Critical Care Medicine, as well as the Medical Director of the Medical Intensive Care Unit and Respiratory Therapy at William P. Clements Jr. University Hospital. He has extensive clinical expertise in managing complex pulmonary conditions and critical care medicine.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Fernando Martinez, faculty for this educational activity, has the following relevant financial relationships: Advisor for Lung Therapeutics; Consultant, Advisor, and Speaker for Boehringer Ingelheim and Chiesi; DSMB for Pliant; Researcher for AstraZeneca, Bristol Myers Squibb, Chiesi, DevPro, and Vicore.

Dr Corey Kershaw, faculty for this educational activity, has the following relevant financial relationships: Consultant, Advisor, and Speaker for Boehringer Ingelheim; Researcher for Avalyn Pharma, Bristol Myers Squibb, Daewoong Pharmaceutical, PureTech Health/Celea Therapeutics, and United Therapeutics.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-361-H01-P

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 30, 2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 1 November 2026 through to 30 September 2027.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.

This continuing education activity is active starting 1 November, 2026 and will expire on 30 September, 2027.

Estimated time to complete this activity: 15 Minutes

Learning objectives

By the end of this activity participants will be able to:

  • Incorporate risk stratification, high‑resolution imaging, and multidisciplinary assessment to differentiate and diagnose IPF and PPF from other ILDs early and accurately.
  • Implement multidisciplinary diagnostic and management strategies to improve timely recognition, referral, and coordinated care for patients with PF.
  • Apply knowledge of mechanisms of action and clinical evidence to treatment decisions, including patient selection and therapy timing.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Let me introduce you to Margaret. So she has been in 3 different clinic rooms over the 6 months before anybody even ordered a pulmonary function test. We're gonna try to sort of figure out why that's happened, uh, what could have been done differently at each of those moments, and, and how that's gonna impact, uh, her, uh, her care. OK? So, here's Margaret. For a long time I put it down to age. I have arthritis, so if the stairs were harder than they used to be, I assumed that was why. What made me take it seriously was the cough, a dry cough that went on for months. I mentioned the breathlessness at several appointments. Each time it was put down to something else. Now, this is one of those polls that I warned you about. So remember that there are a couple of approaches to being able to answer these polls. Uh, and this this question is, how confident are you that you would recognize and act on early ILD in a patient like Margaret? You only got 5 options, so it's easy from not at all confident to completely confident. You're gonna see this question again at the end of the hour. So we wanna see any changes that occur over time. So go ahead and answer away. Hello, I'm Doctor Corey Kershaw. I am a professor of medicine in the division of Pulmonary and Critical Care Medicine at the University of Texas Southwestern Medical Center in Dallas, Texas, and I'm very pleased to join you today. Uh, I'm gonna be talking about a visit that our patient had in her rheumatology clinic. And we're gonna call this the missed window because um I believe you all see that there are some opportunities that go by where we could have intervened, um, at least diagnostically early for our patients. So we'll start here. This is Margaret. We've met her. She's 66 and she's here for a routine rheumatology clinic appointment. Her history is relevant for serial positive rheumatoid arthritis that was diagnosed when she was 61, that's 5 years ago. She's currently managed with methotrexate 20 mg once per week plus folic acid, and this regimen is working quite well for her. Her joints are well-controlled. She used to smoke, 20 pack years, quit at age 55. Um, she worked as a school teacher. She's now retired. She walks daily for exercise, but she admits to us that she is slowing down a bit. Today's visit, when we're discussing things, um, she reports a dry cough, um, for the last 4 months, and she thinks it's related to her allergies, so probably nothing to worry about. Um, on her daily walks, because it is a routine for her, she knows what her, um, capacity is. She's noticed that she's beginning to be a bit more breathless on a hill that was manageable previously. And, you know, she doesn't think anything of it. She thinks it's just deconditioning. She's getting a bit older. Um, she has no respiratory complaints on her own until you ask. Um, so these things did not come up at all until we ask these questions. And on a, um, On our examination, she has crackles in both lung bases when we listen to her chest. So You know, our agenda coming into this appointment, you know, we're as a rheumatologist in this setting, you know, I'm gonna ask about her joint scores. Uh, she takes methotrexate, so we have to do some routine blood tests to, um, Uh, ensure she's not having any toxicity. I asked her about flu vaccinations, important for all of our patients. Um, but there's nothing on the agenda that says anything about her lungs, and I think we'll find that that is very relevant as we go through, um, Margaret's symptoms here. So Let's start, let's go detail by detail here. So the first thing, um, that's relevant for Margaret is she's had rheumatoid arthritis for 5 years and our context here is, um, looking at the possibility that Margaret may have an interstitial lung disease in the setting of her rheumatoid arthritis. And in fact, um, rheumatoid arthritis is a significant risk for ILD. There's a 7.7% lifetime ILD risk in patients with rheumatoid arthritis compared to patients who don't have arthritis. Um, And the reason that's important for us to remember is that a patient comes to us with rheumatoid arthritis and has pulmonary complaints, a dry cough, crackles on exam, we should not default to what in a patient without RA may indeed be true that this is maybe allergy-related. Maybe it's related to her getting older. We have to exclude ILD 7.7% lifetime risk. That's quite significant. So we really need to be attuned. To that possibility and having a, you know, just having it through uh RA throughout your life increases the risk for ILD ninefold. 1 in 13 patients will develop RA will develop ILD when they have RA, um. And We shrugged off Margaret's symptoms. She certainly didn't seem concerned about them. That land right on that baseline that we should be concerned about. Um, and we should not rule out ILD as a consideration just because she's had RA for some time now. And in fact, the medium time that a patient has been diagnosed with rheumatoid arthritis before they develop ILD is 5 years. Um, real-world average 3.3 years, um, from the time the patient's diagnosed with, uh, rheumatoid arthritis until they are diagnosed with ILD and that incidence climbs throughout the first decade of diagnosis. So, you see a patient, you're diagnosing with rheumatoid arthritis, really that first decade, it has to be part of our every clinic assessment. Uh, for pulmonary symptoms because the risk is significant that the patient may develop an ILD during that time. So we need to be very attuned to that possibility. Um, Margaret's labs, let's consider that. So Margaret is, um, CCP positive. And in fact, being CCC positive itself is a notable risk for developing ILD and in fact, a high titer is especially concerning. 3 times the upper limit of normal is considered um a high positive serology and the higher the titer. The stronger the ILD association. So you can see the hazard ratio for developing ILD is 9 in patients that are seronegative, um, in patients that don't have RA and even patients that are, that have RA that don't, that aren't CC positive. They still have a risk, but it's significantly higher if they are CC CCC positive, excuse me. Um, and so certainly in a patient we're seeing in our rheumatology clinic that is CCP positive with the rheumatoid arthritis, very significant risk for developing ILD later on. Margaret has a smoking history. Great that she quit, but that risk, um, her smoking history increases her risk of developing RAILD and that risk does not go away just because she quit. Um, so even ex-smokers still have a risk. Great that she quit smoking, great for other aspects of her health, but it doesn't, um, make the risk for ILD go away. So, the the odds ratio for for RAILD in ever smokers is 2.8. So, The, the things that really go along with her risk is that um in terms of this aspect of her history is she's an ex-smoker and she's seropositive. If you, if you're also a man, the odds ratio goes up to 6.9. Margaret is female, so she doesn't have that stacked risk, but still being an um ever smoker, her odds ratio of developing ILD. 2.8. Um, as part of her visit, um, she gets, uh, a Rodden skin score because it's important according to the, um, SARD ILD guidelines that we exclude patients on the scleroderma spectrum first. She has no skin thickening, which is reassuring because having skin thickening itself would be a risk factor for ILD, but that does not exclude her from the risk because she has other features in her diagnosis that place her at risk of developing ILD. What about her methotrexate? It, it is a Common, I'm gonna use the term misconception that a patient on methotrexate is at risk for developing a fibrosing ILD, um, and in fact, that's not actually true, especially in the setting of somebody with rheumatoid arthritis. Um, being on methotrexate lowers the risk of, um, rheumatoid arthritis and actually prolongs the onset of it developing later from the RA. So, it's so important that when you see a patient in your clinic that you're managing with methotrexate, especially if it's working well, you know, methotrexate is a wonderful drug for the arthralgias that go with rheumatoid arthritis. Um, you hear crackles on exam, you do some other workup and it looks like the patient has an early ILD. Don't stop the methotrexate. In fact, keep it on because that's, you know, you know, perhaps gonna help them, and you should assume that perhaps the ILD is actually from the RA itself and not from the drug. So this is not a risk factor. It actually lowers her risk of developing ILD being on methotrexate. So, let's talk about just some of the other um risks that, you know, we need to consider here and why this is important. So, having subclinical um ILD happens, so the patient doesn't necessarily need to be symptomatic, you know, if you look at patients that have early RA in their diagnosis in their diagnosis diagnosis course, um, they may already have ILD before they have symptoms.